Australian partner to progress Ox-1 Phase 1 trial

AI SummaryClose X

TheraCryf plc has appointed Avance Clinical Pty Ltd to manage the Australian clinical and regulatory preparations for a Phase 1 trial of its Ox-1 programme, targeting addiction and neuropsychiatric disorders. The company expects to complete remaining clinic-enabling documentation in Q4 2026 and aims for approval to proceed with clinical use of Ox-1 by December 31, 2026, subject to approvals. GMP manufacture of the drug substance is complete, with final GLP toxicology data anticipated in early Q4 2026.

Disclaimer*

UK 100